Quintrio
Home

PHARMACEUTICAL PREPARATIONS

60 Degrees Pharmaceuticals, Inc. Common Stock

SXTP

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.454 – $0.542
Volume 21,550
Market cap $2M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.72M
Price / earnings
—
Price / book
0.66×
Price / sales
1.42×
EV / sales
0.7×
EV / EBITDA
-0.1×

Profitability

Earnings per share
-$2.45
Return on assets
-201.19%
Return on equity
-329.59%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.06×
Current ratio
2.32×
Quick ratio
1.78×
Cash ratio
0.64×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$8.89M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SXTP, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$207.9K$162.09K$316.38K$528.56K$307.87K$256.28K$272.23K$148.11K
Cost of revenue$151.1K$85.72K$120.68K$537.69K$50.05K$73.27K$118.08K$111.69K
Gross profit$56.8K$76.38K$195.7K-$9.13K$257.82K$183.01K$154.15K$36.42K
Selling, general and administrative$1.73M$1.89M$1.47M$1.51M$1.63M$1.72M$1.61M$1.22M
Research and development$598.65K$281.46K$638.87K$809.78K$231.91K$370.81K$613.96K$940.06K
Total operating expenses$2.33M$2.17M$2.11M$2.32M$1.86M$2.09M$2.22M$2.16M
Operating income-$2.27M-$2.09M-$1.92M-$2.33M-$1.61M-$1.91M-$2.07M-$2.12M
Interest expense-$1.4K-$1.39K-$3.09K-$1.71K-$1.22K-$1.79K-$1.42K-$1.47K
Income before taxes-$2.27M-$2.09M-$1.44M-$2.32M-$1.73M-$1.88M-$2.05M-$2.16M
Income taxes$0$0-$1.81K$250$0$0-$751$250
Net income-$2.27M-$2.09M-$1.44M-$2.32M-$1.73M-$1.88M-$2.05M-$2.16M
Net income attributable to common shareholders-$2.4M-$2.21M-$1.57M-$2.44M-$1.84M-$2M-$2.18M-$2.27M
EBITDA-$2.31M-$2.02M-$1.72M-$2.3M-$1.65M-$1.85M$1.54M-$2.1M
Basic earnings per share-$0.90-$1.28-$1.46-$2.64-$5.01-$6.25-$9.10-$18.60
Diluted earnings per share-$0.90-$1.28-$1.46-$2.64-$5.01-$6.25-$9.10-$18.60

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Harrow (HROW) Q3 Earnings Lag Estimates

Harrow (HROW) reported Q3 2026 earnings of $0.12 per share, missing the consensus estimate of $0.13 and falling short of prior year's $0.33. The pharmaceutical company posted revenues of $99.3 million, slightly beating expectations. However, the stock has declined 45.1% year-to-date and received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revisions, suggesting continued underperformance ahead.

GlobeNewswire Inc.

60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

60 Degrees Pharmaceuticals reported Q3 2025 financial results with 223% net product revenue increase, but experienced a gross loss due to inventory write-off. The company is exploring new treatment indications for tafenoquine, including potential treatments for canine babesiosis and chronic babesiosis.

GlobeNewswire Inc.

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

Sixty Degrees Pharmaceuticals announced that it will import a limited quantity of KODATEF® (tafenoquine) from Australia to ensure the continuity of ARAKODA® (tafenoquine) supply in the U.S. ARAKODA and KODATEF are identical products, and the company is taking this proactive step to maintain the availability of tafenoquine for malaria prophylaxis.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jan 20, 20261-for-4reverse split
Feb 24, 20251-for-5reverse split
Aug 12, 20241-for-12reverse split